Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.34 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059345 | 0.81 | PDE10A (0.41) | LIMK1ALOX5APFEN1EPHX2CRHR1 | |
| SCHEMBL4050597 | 0.80 | EPHX2 (0.40) | LIMK1EPHX2NFE2L2CRHR1LIMK2 | |
| SCHEMBL2599089 | 0.73 | LIMK1 (0.38) | LIMK1EPHX2CRHR1LIMK2ALDH1A1 | |
| SCHEMBL4056620 | 0.73 | LIMK1 (0.45) | LIMK1EPHX2LIMK2KDM4ESMN1; SMN2 | |
| SCHEMBL4057442 | 0.72 | LIMK1 (0.44) | LIMK1EPHX2CRHR1LIMK2KDM4E | |
| SCHEMBL18326358 | 0.71 | APLNR (0.40) | NFE2L2 | |
| SCHEMBL4051071 | 0.70 | ALOX5AP (0.41) | ALOX5APFEN1 | |
| SCHEMBL27315812 | 0.70 | KCNH2 (0.33) | KDM4ESMN1; SMN2NPSR1 | |
| SCHEMBL4056368 | 0.69 | PDK2 (0.41) | LIMK1ALOX5APFEN1KDM4EALDH1A1 | |
| SCHEMBL3717880 | 0.68 | ACACB (0.38) | LIMK1ALDH1A1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | LIMK1 2767/4885ALOX5AP 2793/4885FEN1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.